Development and validation of a novel stability-indicating reversed-phase high-performance liquid chromatography method for assay of loratadine and determination of its related compounds.
Loratadine is an important active pharmaceutical ingredient used in a wide variety of prescription and over-the-counter products for the treatment and relief of allergy symptoms. A novel stability-indicating gradient ion-pair RP-HPLC method for assay of loratadine and determination of both of its degradation compounds and process impurities has been developed. This method can separate loratadine from its eight structurally related compounds; it can also separate all of the related compounds from each other in less than 20 min. The stability-indicating capability of this method has been demonstrated by analyzing aged stability samples of loratadine. A 15 cm x 4.6 mm id YMC-Pack Pro C18 HPLC column was the primary column and a 15 cm x 4.6 mm id SunFire C18 column has been identified as an alternate (truly equivalent) column for this method. This gradient method uses mobile phases consisting of acetonitrile and an aqueous solution of 10 mM sodium acetate and 5 mM sodium dodecyl sulfate at pH 5.5. The new HPLC method was validated according to International Conference on Harmonization guidelines and proved to be suitable for routine QC use.
Lu
Jun
J
Merck & Co. Inc., ACDS-SAS, Union, NJ 07083, USA. jun.lu2@merck.com
Wei
Yu-Chien
YC
Markovich
Robert J
RJ
Rustum
Abu M
AM
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004355:Drug Stability; D039563:Histamine H1 Antagonists, Non-Sedating / Q000032:analysis*; D057230:Limit of Detection; D017336:Loratadine / Q000032:analysis* / Q000737:chemistry; D015203:Reproducibility of Results
D039563:Histamine H1 Antagonists, Non-Sedating; D017336:Loratadine